Overview

Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera

Status:
Completed
Trial end date:
2018-01-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is the identification of the maximum tolerated dose (MTD) of the investigational medicinal product. Moreover the safety and tolerability will be assessed and an exploratory analysis of efficacy and biomarker modulation will be performed.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AOP Orphan Pharmaceuticals AG
Treatments:
Interferon-alpha
Interferons
Peginterferon alfa-2b